Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.

Muscle wasting disorders, including sarcopenia and skeletal muscle atrophy, are increasingly prevalent among older adults and those with metabolic comorbidities. Sarcopenia, a progressive age-associated condition, involves the decline in skeletal muscle mass, strength, and physical performance, affecting millions of people...

🗓️ 2025-12-16
📰 Publication: Aging And Disease
Read MoreGlucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.

Skeletal Muscle HSF1 Alleviates Age-Associated Sarcopenia and Mitochondrial Function Decline via SIRT3-PGC1α Axis.

Age-related sarcopenia, characterized by progressive loss of skeletal muscle mass and strength, impacts metabolic health and quality of life in the elderly. Heat shock factor 1 (HSF1) is a transcription factor that orchestrates cellular responses to various stresses, while its...

🗓️ 2025-12-16
Read MoreSkeletal Muscle HSF1 Alleviates Age-Associated Sarcopenia and Mitochondrial Function Decline via SIRT3-PGC1α Axis.

CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

BACKGROUND

Advanced metastasis produces cachexia, a complex skeletal muscle wasting syndrome that accounts for one-third of patient deaths. There is currently no approved drug therapy for cancer cachexia. Cancer-associated fibroblasts (CAF) within tumors have been hypothesized to contribute to cachexia, but...

🗓️ 2025-12-15
📰 Publication: Journal Of Biomedical Science
Read MoreCXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

Decorin Deficiency Promotes D-Galactose-Induced Skeletal Muscle Atrophy and Fibrosis by Regulating ITGB1/Akt/mTOR Signalling Pathway.

BACKGROUND

Primary sarcopenia is an age-associated disorder with progressive and generalised loss of skeletal muscle strength and mass. Skeletal muscle fibrosis is one of the significant pathological manifestations of age-associated sarcopenia. Decorin, a small dermatan-sulfate proteoglycan, participates in extracellular matrix assembly....

🗓️ 2025-12-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDecorin Deficiency Promotes D-Galactose-Induced Skeletal Muscle Atrophy and Fibrosis by Regulating ITGB1/Akt/mTOR Signalling Pathway.

C2C12-Derived ApoVs Promote Skeletal Muscle Development and Ameliorate Age-Related Muscle Loss Through Igf1r/PI3K/AKT/mTOR Pathway.

BACKGROUND

Apoptosis coincides with the differentiation of skeletal myoblasts, and numerous studies have shown that the apoptotic activity is required for myogenic differentiation. Although the role of apoptosis in skeletal muscle differentiation has been well documented, its mechanism is largely unknown.

METHODS

Apoptotic...

🗓️ 2025-12-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreC2C12-Derived ApoVs Promote Skeletal Muscle Development and Ameliorate Age-Related Muscle Loss Through Igf1r/PI3K/AKT/mTOR Pathway.

Sex-specific differences between C-reactive protein and appendicular lean soft tissue index in heart failure: findings from the National Health and Nutrition Examination Survey.

INTRODUCTION

Heart failure (HF) is often accompanied by muscle wasting and elevated C-reactive protein (CRP). This study aimed to examine the association between CRP and appendicular lean soft tissue index (ALSTI) in patients with HF, focusing on potential sex differences.

METHODS

Using data...

🗓️ 2025-12-05
📰 Publication: Acta Cardiologica
Read MoreSex-specific differences between C-reactive protein and appendicular lean soft tissue index in heart failure: findings from the National Health and Nutrition Examination Survey.

Assessing SARCopenia with ecHOgraphy in Community-Dwelling Older Adults: A Validation Study (SARCHO).

OBJECTIVES

To prospectively evaluate the diagnostic accuracy of the sarcopenia echography (SARCHO) point-of-care ultrasound protocol for diagnosing sarcopenia, in accordance with the European Working Group on Sarcopenia in Older People 2.

METHODS

This study was conducted as a single-center prospective, feasibility diagnostic accuracy...

🗓️ 2025-12-04
Read MoreAssessing SARCopenia with ecHOgraphy in Community-Dwelling Older Adults: A Validation Study (SARCHO).

Myostatin, activin-A and follistatin are produced by the tumor in head and neck cancer and likely contribute to sarcopenia: a case-control, cross-sectional exploratory study.

BACKGROUND AND AIMS

Myostatin (M), activin-A (A) and follistatin (F), three TGF-β superfamily members, play a role in cancer sarcopenia. The aim of our study was to assess the association of MAF in head and neck cancer (HNC) skeletal muscle loss.

MATERIALS...

🗓️ 2025-12-04
Read MoreMyostatin, activin-A and follistatin are produced by the tumor in head and neck cancer and likely contribute to sarcopenia: a case-control, cross-sectional exploratory study.

Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.

Sarcopenia is a progressive age-related condition characterized by the decline of skeletal muscle mass and function. Its development involves multiple cellular and molecular mechanisms, including chronic inflammation, apoptosis, mitochondrial dysfunction, and impaired muscle regeneration. Human umbilical cord mesenchymal stromal cells...

🗓️ 2025-12-03
Read MoreUmbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.

Postmenopausal Sarcopenia and Alzheimer's disease: The interplay of Mitochondria, Insulin resistance, and Myokines.

As life expectancy increases, cognitive impairments such as Alzheimer's disease (AD) create serious problems for older adults. Women regardless of ethnicity and age group, are disproportionately affected, accounting for two-thirds of AD cases, with post-menopausal women representing over 60% of...

🗓️ 2025-12-02
📰 Publication: Neuroscience And Biobehavioral Reviews
Read MorePostmenopausal Sarcopenia and Alzheimer's disease: The interplay of Mitochondria, Insulin resistance, and Myokines.

Negative Impact of p21-Activated Kinase 4-Mediated AMP-Activated Protein Kinase Inhibition on Sarcopenia in Mice and Humans.

We recently identified that AMP-activated protein kinase (AMPK) α2 phosphorylation at S491 is mediated by p21-activated kinase 4 (PAK4), leading to muscular and systemic insulin resistance. This study examined how muscle PAK4 deletion affects atrophy in male mice and its...

🗓️ 2025-12-02
Read MoreNegative Impact of p21-Activated Kinase 4-Mediated AMP-Activated Protein Kinase Inhibition on Sarcopenia in Mice and Humans.

Statin Use Is Associated With a Decline in Muscle Function and Mass Over Time, Irrespective of Statin Pharmacogenomic Score.

BACKGROUND

Statins are cholesterol-lowering drugs widely prescribed for preventing cardiovascular diseases. They may cause adverse effects on skeletal muscle, but it remains unclear whether they affect muscle function and mass. We aimed to evaluate the association between statin use and muscle...

🗓️ 2025-11-21
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreStatin Use Is Associated With a Decline in Muscle Function and Mass Over Time, Irrespective of Statin Pharmacogenomic Score.

The Monocrotaline Model of Hypertension Leads to Cachexia in Male but Not Female Mice.

BACKGROUND

The monocrotaline (MCT) model of cardiac cachexia is a pharmaceutical approach to pulmonary hypertension that has been used to study heart failure and muscle wasting in rodents; however, little is known of how this pyrrolizidine alkaloid leads to peripheral changes...

🗓️ 2025-11-21
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe Monocrotaline Model of Hypertension Leads to Cachexia in Male but Not Female Mice.

Mitochondrial stress bridge: Could muscle-derived extracellular vesicles be the missing link between sarcopenia, insulin resistance, and chemotherapy-induced cardiotoxicity?

Sarcopenia is currently considered a systemic condition that goes beyond muscle atrophy to include multifunctional metabolic and cardiovascular dysfunction. The mediators between skeletal muscle loss and entire body insulin resistance and increased vulnerability to cardiotoxicity caused by chemotherapy are not...

🗓️ 2025-11-21
📰 Publication: Biomedicine & Pharmacotherapy
Read MoreMitochondrial stress bridge: Could muscle-derived extracellular vesicles be the missing link between sarcopenia, insulin resistance, and chemotherapy-induced cardiotoxicity?

Exploring the potential of ginseng-derived compounds in treating cancer cachexia.

Cancer cachexia is a complex wasting syndrome characterized by significant loss of body weight and muscle mass in patients with advanced cancer. The disease is associated with increased systemic inflammation, altered neurohormonal signaling, and, in particular, an increased catabolic rate...

🗓️ 2025-11-21
📰 Publication: Journal Of Ginseng Research
Read MoreExploring the potential of ginseng-derived compounds in treating cancer cachexia.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 – Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 – The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4: 89–94.

Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793–799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014; 5: 1–3.

Argiles JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology 2015; 22: 100–106.

Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015; 6: 197–207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!